基于价值定价的比美吉珠单抗的药物经济学评价  

Pharmacoeconomic evaluation of Bimekizumab based on value-based pricing

作　　者：万小敏[1,2] 刘金艳 郑绘[4] 刘俏[1,2] 易利丹[1,2] 罗霞[1,2] WAN Xiaomin;LIU Jinyan;ZHENG Hui;LIU Qiao;YI Lidan;LUO Xia(Department of Pharmacy,the Second Xiangya Hospital of Central South University,Hunan Changsha 410011,China;Institute of Clinical Pharmacy,Central South University,Hunan Changsha 410011,China;Department of Forensic Medicine,School of Basic Medicine,Central South University,Hunan Changsha 410000,China;Department of Pharmacy,Hospital of Chengdu University of Traditional Chinese Medicine,Sichuan Chengdu 610075,China)

机构地区：[1]中南大学湘雅二医院药学部,湖南长沙410011 [2]中南大学临床药学研究所,湖南长沙410011 [3]中南大学基础医学院法医学系,湖南长沙410000 [4]成都中医药大学附属医院药剂部,四川成都610075

出　　处：《中国医院药学杂志》2024年第4期372-376,383,共6页Chinese Journal of Hospital Pharmacy

基　　金：湖南省自然科学基金课题(编号:2021JJ40817,2022JJ80040,2023JJ60503);湖南省卫健委科研项目(编号:202113050611,202113050283,202213053462)。

摘　　要：目的:比美吉珠单抗和司库奇尤单抗治疗中重度斑块状银屑病进行药物经济学评价,并基于价值给出比美吉珠单抗定价建议。方法:本研究从中国医疗卫生角度出发,利用TreeAge Pro软件构建马尔可夫模型,评价比美吉珠单抗和司库奇尤单抗单药治疗策略下比美吉珠单抗不同定价时的总成本与总健康产出,并通过敏感性分析验证模型的稳健性。该模型中的参数和数据来源于已发表的文献和官方网站。结果:当比美吉珠单抗的价格为1 377元/160 mg时,比美吉珠单抗组的总成本为222 073元,司库奇尤单抗组的总成本为190 425元,增量成果-效果比(ICER)为85 662.90元/质量调整生命年(QALY),接近2022年1倍人均国内生产总值(GDP,85 698元)。当比美吉珠单抗的价格为1 848元/160 mg时,比美吉珠单抗组的总成本为285 475元,司库奇尤单抗组的总成本为190 425元,ICER为257 275.77元/QALY,接近2022年3倍人均国内生产总值(3GDP,257 094元)。当比美吉珠单抗和司库奇尤单抗的价格相同时,ICER为16 799.14元/QALY,此时比美吉珠单抗具有更明显的成本-效果优势。结论:基于价值定价建议,与司库奇尤单抗相比,当WTP为85 698元/QALY时,比美吉珠单抗的价格需低于1 377元/160 mg时,才可能具有成本-效果优势;当WTP为257 094元/QALY时,比美吉珠单抗的价格需低于1 848元/160 mg时,才可能具有成本-效果优势。OBJECTIVE In this study,pharmacoeconomic evaluation was conducted to compare bimekizumab and secukinumab in the treatment of moderate-to-severe plaque psoriasis,and pricing recommendations for bimekizumab were given based on its value.METHODS From the perspective of medical and health care in China,a Markov model was constructed using TreeAge Pro software to evaluate the total costs and overall health outcomes of bimekizumab under different pricing compared to secukinumab monotherapy strategies.Sensitivity analysis was employed to verify the robustness of the model.The parameters and data in this model were derived from published literature and official websites.RESULTS When the price of bimekizumab was 1377 yuan/160 mg,the total cost of bimekizumab group was 222073 yuan,the total cost of secukinumab group was 190425 yuan,with an incremental cost-effectiveness ratio(ICER)of 85662.90 yuan·QALY–1,nearly matching the per capita GDP in 2022(85698 yuan).When the price of bimekizumab was 1848 yuan/160mg,the total cost of bimekizumab group was 285475 yuan,the total cost of secukinumab group was 190425 yuan,with an ICER of 257275.77 yuan·QALY–1,nearly 3 times the per capita GDP in 2022(257094 yuan).When the price of bimekizumab and secukinumab were the same,ICER was 16799.14 yuan·QALY–1,which indicated that bimekizumab is more cost-effective.CONCLUSION The value-based pricing suggests that compared with secukinumab,bimekizumab should be priced below 1377 yuan/160mg when willingness to pay(WTP)is 85698 yuan·QALY–1,and below 1848 yuan/160 mg when WTP is 257,094 yuan·QALY–1 to have a cost-effectiveness advantage.

关 键 词：比美吉珠单抗 中重度斑块状银屑病 马尔可夫模型 成本-效用 基于价值定价 

分 类 号：R956[医药卫生—药学]